Abstracts tagged "Systemic lupus erythematosus (SLE)"

Abstract Number: 0559 • ACR Convergence 2023
Development of Charlson Comorbidity Index (CCI) Comorbidities and CCI Score in Danish Nationwide Cohort of 3,178 Patients with Newly Diagnosed Systemic Lupus Erythematosus
Renata Baronaite Hansen, Copenhagen Research Center for Autoimmune Connective Tissue Diseases, Copenhagen University Hospital, Rigshospitalet, Copenhagen, Denmark
Background/Purpose: Comorbidity risk is remarkably increased in patients with Systemic Lupus Erythematosus (SLE) compared with the general population. A better understanding of comorbidity development in…
Abstract Number: 0575 • ACR Convergence 2023
The Real-World Utility of a Lupus Activity Monitoring Panel in the United States Community Rheumatologist Practice
Andrew Concoff¹, Laura Moore-Schiltz², Vijay Nadipelli³, Tyler O'Malley¹, Karen Worley⁴, Allison Petrilla², Debra Zach¹, Scott B. Robinson², Sara Taiyari⁵, Barton Jones² and Bernard Rubin⁶, ¹Exagen, Vista, CA, ²Inovalon, Bowie, MD, ³GlaxoSmithKline, Philadelphia, PA, ⁴GlaxoSmithKline, US Value Evidence and Outcomes, Cincinnati, OH, ⁵GlaxoSmithKline, Collegeville, PA, ⁶GlaxoSmithKline, US Medical Affairs and Immuno-inflammation, Durham, NC
Background/Purpose: Patients with active SLE have periods of uncontrolled disease activity that are associated with a greater risk for developing irreversible organ damage. Current standard…
Abstract Number: 0593 • ACR Convergence 2023
Lupus Nephritis of the Spanish National Registry of Belimumab in Patients with Systemic Lupus Erythematosus
María laiño¹, Monica Enguita², Pablo Navarro³, Javier Loricera⁴, Angel Garcia-Aparicio⁵, Carmen Lasa⁶, Vanesa Calvo Río⁷, Adela Gallego⁸, Clara Moriano Morales⁹, Javier Narvaez¹⁰, MARIA IRENE CARRION BARBERA¹¹, Jordi Camins-Fàbregas¹², Joaquin Maria Belzunegui Otano¹³, Ana Urruticoechea¹⁴, Leticia del Olmo Perez¹⁵, Santos Castañeda¹⁶, Patricia Quiroga¹⁶, Ivette Casafont-Sole¹⁷, Juan Ramon De Dios Jimenez De Aber¹⁸, Marta López¹⁹, Judit Font Urgelles²⁰, Rafaela Ortega Castro²¹, Marta Garijo Bufort²², Jorge Juan Fragio²³, Ignacio Vázquez²⁴, Mamen Ortega²⁵, Aaron Fariñas²⁶, Cilia Peralta²⁷, Juan María Blanco²⁸, Sergi Heredia Martin²⁹, Maria Valvanera Pinillos³⁰, Eztizen Labrador-Sánchez³¹, Piter Jose Cossio Jimenez³², Carlos Vazquez Galeano³³ and Vicente Aldasoro¹, ¹Hospital Universitario de Navarra, Pamplona, Spain, ²Navarrabiomed-Unidad de Metodología, Pamplona, Spain, ³Rheumatology, Hospial Universitario Puerta de Hierro, Majadahonda, Spain, ⁴Hospital Universitario Marqués de Valdecilla, Santander, Spain, ⁵Hospital Universitario de Toledo, Toledo, Spain, ⁶Hospital Universitario Marqués de Valdecilla, IDIVAL., La Cavada, Spain, ⁷Valdecilla Hospital, Santander, Spain, ⁸Complejo Hospitalario Universitario de Badajoz, Badajoz, Spain, ⁹Rheumatology, Hospital Universitario de León, León, Spain, ¹⁰Hospital Universitario de Bellvitge, Barcelona, Spain, ¹¹Hospital del Mar/Parc de Salut Mar-IMIM, Barcelona, Spain, ¹²Hospital General de Granollers, Granollers, Spain, ¹³University Hospital Donostia, Donostia-San Sebasti, Spain, ¹⁴Hospital Can Misses, Ibiza, Spain, ¹⁵Hospital Nuestra Señora del Prado, Talavera de la Reina, Spain, ¹⁶Hospital Universitario de la Princesa, Madrid, Spain, ¹⁷Hospital Universitari Germans Trias i Pujol, Badalona, Spain, ¹⁸Hospital de Araba, Alava, Spain, ¹⁹Hospital Universitario Arava, Pamplona, Spain, ²⁰Hospital Universitario German Trias i Pujol,, Badalona, Spain, ²¹Hospital Reina Sofía, Cordoba, Spain, ²²Hospital de Sagunto, Valencia, Spain, ²³Hospital General Universitario Valencia, Valencia, Spain, ²⁴H. U. Dr. Peset, Valencia, Spain, ²⁵Hospital Universitario de Getafe, Getafe, Spain, ²⁶Complejo Asistencial Universitario de Palencia, Palencia, Spain, ²⁷Hospital Clínico Universitario Lozano Blesa, Zaragoza, Spain, ²⁸Hospital Universitario de Basurto, Bilbao, Spain, ²⁹Complex Hospitalari Moisès Broggi, Barcelona, Spain, ³⁰Hospital Universitario San Pedro, Logroño, Spain, ³¹Hospital Universitario San Pedro, Laguardia, Spain, ³²HOSPITAL REINA SOFIA, Tudela, Spain, ³³ZARAGOZA, Madrid, Spain
Background/Purpose: Belimumab (BLM) is a B-cell stimulating factor (BlyS) monoclonal antibody, approved in 2022 for the treatment of lupus nephritis (NL) and since 2011 for…
Abstract Number: 0733 • ACR Convergence 2023
Global Identification of Lupus Genetic Risk Variants Facilitating the Type I Interferon Pathway Through CRISPR-based Genomic Screening
Guojun Hou¹, Xinyi Zhu¹, Yutong Zhang¹, Zhaorui Cheng¹ and Nan Shen², ¹Shanghai Institute of Rheumatology, Renji Hospital, School of Medicine, Shanghai Jiao Tong University (SJTUSM), Shanghai, China, ²Shanghai Jiao Tong University School of Medicine, Shanghai, China
Background/Purpose: Genome-Wide Association Studies (GWAS) have unveiled over 1000 risk variants for lupus, predominantly situated in non-coding genomic regions. Their functional roles, especially their potential…
Abstract Number: 0851 • ACR Convergence 2023
Lupus Nephritis Flares Linked to Platelet Activation During Gut Pathobiont Blooms
Abhimanyu Amarnani¹, Doua Azzouz², MacIntosh Cornwell³, David Mieles³, Peter Izmirly⁴, Jill Buyon⁵, Kelly Ruggles⁶ and Gregg Silverman⁵, ¹NYU Langone Medical Center, New York, NY, ²NYU Langone Health ( School of medicine), New York, NY, ³New York University, New York, NY, ⁴New York University School of Medicine, New York, NY, ⁵NYU Grossman School of Medicine, New York, NY, ⁶NYU Langone, New York, NY
Background/Purpose: Systemic lupus erythematosus (SLE) is associated with gut microbiota dysbiosis, and community imbalance can coincide with flares of Lupus nephritis (LN). Herein, we sought…
Abstract Number: 0906 • ACR Convergence 2023
Paired Autoantibody Specificities from Serum and Immune Complexes Do Not Fully Explain the Circulating Immune Complex Load in Systemic Lupus Erythematosus: A Study on 530 Patients
Enrico Fuzzi¹, Anna Svanqvist², Christine Westerberg², Agneta Zickert³, Iva Gunnarsson⁴, Johan Rönnelid² and Elisabet Svenungsson⁵, ¹Karolinska University Hospital, Stockholm, Sweden, ²Department of Immunology, Genetics and Pathology, Uppsala University Hospital, Uppsala, Sweden, ³Karolinska University Hospital, Stockholm, Sweden, Stocksund, Sweden, ⁴Karolinska Institutet, Stockholm, Sweden, ⁵Department of Medicine Solna, Unit of Rheumatology, Karolinska Institutet and Karolinska University Hospital, Stockholm, Sweden
Background/Purpose: Systemic Lupus Erythematosus (SLE) is a prototypical autoimmune disease where autoantibody production and immune complex (IC) formation play a key role. Which antibodies contribute…
Abstract Number: 0927 • ACR Convergence 2023
A Complex Interplay Among Gut Lachnoclostidium, HLA Haplotype DRB1*07:01, and the TNF Superfamily in Anti-Ro+ Women with a Spectrum of Preclinical and Clinical Autoimmunity Whose Children Have Neonatal Lupus
Robert Clancy¹, Caroline Izmirly¹, Miranda Marion², Nicola Fraser¹, Joel Guthridge³, Timothy Howard², Peter Izmirly⁴, Mala Masson⁵, Jill Buyon¹, Judith James³ and Carl Langefeld⁶, ¹NYU Grossman School of Medicine, New York, NY, ²Wake Forest University, Winston-Salem, NC, ³Oklahoma Medical Research Foundation, Oklahoma City, OK, ⁴New York University School of Medicine, New York, NY, ⁵New York University, New York, NY, ⁶Wake Forest University School of Medicine, Winston-Salem, NC
Background/Purpose: Mothers of children with neonatal lupus (NL) are often clinically asymptomatic or have insufficient criteria for a formal rheumatologic diagnosis, despite having high titers…
Abstract Number: 1213 • ACR Convergence 2023
Using Patient-Reported Disease Activity in a Population-Based Cohort to Predict Systemic Lupus Erythematous Hospitalization and Emergency Room Visits
S. Sam Lim¹, Sandra Wu², Ryan Ross³, Gaobin Bao¹, Megan Richards³, Liisa Palmer³ and Gary Bryant⁴, ¹Emory University, Atlanta, GA, ²AstraZeneca, Hockessin, DE, ³Merative, Cambridge, MA, ⁴AstraZeneca, New Castle, DE
Background/Purpose: Systemic lupus erythematosus (SLE) is a multisystem autoimmune disease that has a large range of clinical manifestations, some of which can be severe. Reducing…
Abstract Number: 1254 • ACR Convergence 2023
Outcome of Pediatric Lupus in South Asia: Data from Indian SLE Inception Cohort for Research (INSPIRE)
Amita Aggarwal¹, Ranjan Gupta², Liza Rajasekhar³, Ashish J Mathew⁴, Parasar Ghosh⁵, Chengappa Kavadichanda⁶, Vineeta Shobha⁷, Bidyut Das⁸, Manish Rathi⁹, Avinash Jain¹⁰ and Able Lawrence¹, ¹Sanjay Gandhi Postgraduate Institute of Medical Sciences (SGPGIMS), Lucknow, India, ²All India Institute of Medical Sciences, New Delhi, India, ³Nizam's Institute of Medical Sciences, Madhapur, India, ⁴Christian Medical College, Vellore, India, ⁵Govt of West Bengal, Kolkata, India, ⁶Jawaharlal Institute of Postgraduate Medical Education and Research, Puducherry, India, ⁷St. John's National Academy of Health Science, Bangalore, India, ⁸SCB medical college, Cuttack, India, ⁹Postgraduate Institute of Medical education and Research, Chandigarh, India, ¹⁰SMS Medical College, Lucknow, India
Background/Purpose: Juvenile onset SLE (jSLE) has more severe disease and has poorer outcome as compared to adults SLE. Ethnicity affects clinical course and disease outcome…
Abstract Number: 1449 • ACR Convergence 2023
Evaluation of Progression from Preclinical to Systemic Autoimmune Rheumatic Disease
Joan Wither¹, Dennisse Bonilla², Zareen Ahmad¹, Arthur Bookman³, Linda Hiraki⁴, Earl Silverman⁵, Mohammad Movahedi¹, Sindhu Johnson⁶ and Hana Salem Alahmari⁷, ¹University of Toronto, Toronto, ON, Canada, ²University Health Network, Toronto, ON, Canada, ³Toronto Western Hospital, Toronto, ON, Canada, ⁴The Hospital for Sick Children, Toronto, ON, Canada, ⁵Silverman, Toronto, ON, Canada, ⁶Institute of Health Policy, Management, and Evaluation, University of Toronto, Toronto, ON, Canada, ⁷Toronto Scleroderma Program, Mount Sinai Hospital, Toronto Western Hospital, Division of Rheumatology, Department of Medicine, University of Toronto, Toronto, ON, Canada
Background/Purpose: To evaluate the development of a systemic autoimmune rheumatic disease (SARD) in undifferentiated and asymptomatic individuals with antinuclear antibodies (ANA). We evaluated fulfillment of…
Abstract Number: 1466 • ACR Convergence 2023
Impact of Co-morbid Depression on Systemic Lupus Erythematosus Hospitalizations: Insights from National Readmission Database 2020
Shreena Kamlesh Gandhi¹, Abhiram Challa², Sandhya Shri Kanniyaram³, Arnav Kamat⁴, Tejasri Polana⁵ and Kaleb Michaud⁶, ¹Kansas University School of Medicine, Wichita, KS, ²KU School of Medicine, Wichita, KS, ³John H. Stroger Jr. Hospital of Cook County, Chicago, IL, ⁴NYCH+H/Woodhull, New York, NY, ⁵Jawaharlal Nehru Medical College, Belgaum, Belgaum, India, ⁶University of Nebraska Medical Center, Omaha, NE
Background/Purpose: SLE patients are prone to hospitalizations and readmissions compared to general population. Depression is highly prevalent among patients with SLE and is an important…
Abstract Number: 1483 • ACR Convergence 2023
High Chronicity Index of the Modified NIH (National Institute of Health) Scoring System of Lupus Nephritis Is Associated with Increased Risk of End-stage Kidney Disease: A Retrospective Single-center Study
Shiori Nakagawa, Yasunori Iwata, Takahiro Yuasa, Keisuke Sako, Keisuke Horikoshi, Taichiro Minami, Megumi Oshima, Tadashi Toyama, Shinji Kitajima, Akinori Hara, Norihiko Sakai, Miho Shimizu and Takashi Wada, Department of Nephrology, Kanazawa University Hospital, Kanazawa, Japan
Background/Purpose: Lupus nephritis (LN) is a major manifestation which develops in more than 50% of patients with systemic lupus erythematosus (SLE), and is also a…
Abstract Number: 1500 • ACR Convergence 2023
Cumulative Infections by Week 52 Among Patients with SLE: A Summary of Data from Placebo-Controlled Belimumab Studies
Saira Sheikh¹, Kevin Withrop², Jinoos Yazdany³, Sandra Navarra⁴, Tatsuya Atsuma⁵, Paula Curtis⁶, Jose Miyar Olaiz⁷, Christine Henning⁸, Roger A. Levy⁹, William Stohl¹⁰ and Daniel Wallace¹¹, ¹University of North Carolina at Chapel Hill, Chapel Hill, NC, ²Oregon Health & Science University, Schools of Medicine and Public Health,, Portland, OR, ³University of California, General Department of Medicine, Division of Rheumatology, San Francisco, CA, ⁴University of Santo Tomas Hospital, Joint and Bone Center, Manila, Philippines, ⁵Hokkaido University, Department of Rheumatology, Endocrinology and Nephrology, Sapporo, Japan, ⁶GlaxoSmithKline, R&D Biostatistics, Brentford, United Kingdom, ⁷GlaxoSmithKline, Safety Evaluation and Risk Management, Brentford, United Kingdom, ⁸GlaxoSmithKline, US Medical Affairs, Durham, NC, ⁹GlaxoSmithKline, Global Medical Affairs, Collegeville, PA, ¹⁰University of Southern California Keck School of Medicine, Division of Rheumatology, Los Angeles, CA, ¹¹Cedars-Sinai Medical Center, Los Angeles, CA
Background/Purpose: Patients with SLE have a high risk of infections, which remains a common cause of mortality in this population.1 This infection risk can result…
Abstract Number: 1597 • ACR Convergence 2023
Staphylococcus Aureus Peptidoglycan Induces Pathogenic Autoantibody Production via Autoreactive B Cell Receptor Clonal Selection, Implications in Systemic Lupus Erythematosus
Wangbin Ning, Gary Gilkeson and Wei Jiang, Medical University of South Carolina, Charleston, SC
Background/Purpose: There is an intricate interplay between the microbiome and the immune response impacting the development of normal immunity and autoimmunity. However, we do not…
Abstract Number: 1694 • ACR Convergence 2023
Transcriptomic Analysis of the Impact of Iberdomide on Patients with SLE
Prathyusha Bachali¹, Shimon Korish², Yanhua Hu³, Peter Schafer⁴, Amrie Grammer¹ and Peter Lipsky¹, ¹AMPEL BioSolutions, Charlottesville, VA, ²Bristol Myers Squibb, Summit, NJ, ³Bristol Myers Squibb, Princeton, NJ, ⁴Bristol Myers Squibb, Belle Mead, NJ
Background/Purpose: Iberdomide is a high affinity cereblon ligand that promotes ubiquitylation and proteasomal degradation of Ikaros (IKZF1) and Aiolos (IKZF3) transcription factors and, thereby altering…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].